Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27197937 | 0.88 | SPR (0.31) | SPR | |
| SCHEMBL4183478 | 0.88 | SPR (0.31) | SPR | |
| SCHEMBL20601948 | 0.81 | EPHX2 (0.42) | MEN1KMT2A | |
| SCHEMBL20213981 | 0.79 | — | — | |
| SCHEMBL1006759 | 0.78 | TSHR (0.36) | SPRALDH1A1 | |
| SCHEMBL14157439 | 0.78 | CA12 (0.33) | SPR | |
| SCHEMBL2771480 | 0.75 | ADRB3 (0.39) | ALDH1A1 | |
| SCHEMBL28615553 | 0.74 | HSD11B1 (0.34) | HSD11B1 | |
| SCHEMBL146591 | 0.74 | MAPT (0.37) | ALDH1A1MEN1KMT2A | |
| SCHEMBL4651751 | 0.74 | LMNA (0.33) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024110215-A1 | PESTICIDALLY ACTIVE CYCLIC AMINE COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2024-05-30 | — | — | WO | disclosed |
| EP-4323343-A2 | PYRIDINE DERIVATIVES AND THEIR USE AS PESTICIDE | Syngenta Crop Protection AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| US-20230083376-A1 | BRM Targeting Compounds And Associated Methods Of Use | PRELUDE THERAPEUTICS, INCORPORATED | 2023-03-16 | — | — | US | disclosed |
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | TEIJIN PHARMA LIMITED (JP) | 2021-08-10 | — | — | US | disclosed |
| EP-3813813-A1 | COMPOUNDS | CTXT Pty Limited (AU) | 2021-05-05 | — | — | EP | disclosed |
| EP-3546458-B1 | ((PYRIDIN-2-YL)-AMINO)PYRIDO[3,4-D]PYRIMIDINE AND ((PYRIDAZIN-3-YL)-AMINO)PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES AS CDK4/6 INHIBITORS FOR TREATING E.G. RHEUMATOID ARTHRITIS, ARTERIOSCLEROSIS, PULMONARY FIBROSIS, CEREBRAL INFARCTION OR CANCER | TEIJIN PHARMA LTD (JP) | 2021-01-06 | — | — | EP | disclosed |
| CN-111094269-A | Heterocyclylmethylene derivatives and their use as mGluR5 receptor modulators | 瑞蔻达蒂化学制药公司 | 2020-05-01 | — | — | CN | disclosed |
| EP-3546458-A1 | PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Teijin Pharma Limited (JP) | 2019-10-02 | — | — | EP | disclosed |
| CN-101331115-A | Derivatives for modulating ion channels | VERTEX PHARMA (US) | 2008-12-24 | — | — | CN | disclosed |
| EP-1487803-A1 | INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY | Aventis Pharma S.A. (FR) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003078402-A1 | INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY | AVENTIS PHARMA S.A. (FR) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230083376-A1 | BRM Targeting Compounds And Associated Methods Of Use | ADRM1, BRDT, RBX1 | SPR 1360/4885ALDH1A1 4038/4885MEN1 3067/4885 |
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | CDK4, CDK6, CDK16 | SPR 2952/4885ALDH1A1 964/4885MEN1 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.